Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in unresectable mesothelioma
NCT05455424Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jul 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of niraparib in malignant mesothelioma (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Progression-Free Survival at 18 months. Started Jul 2022; status: completed.
02
Drugs
niraparib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT05455424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455424.